The impact of genotypes present at the rs1044457 locus on drug pharmacokinetics has been emphasized in various studies.[7, 8] Although there is evidence suggesting that CMPK1 polymorphisms affect chemotherapy outcomes, specific research focusing on the rs1044457 polymorphism in the context of metastatic non‐small cell lung cancer (NSCLC) is not directly available in the current literature. The gene discussed is CMPK1; the disease is non-small cell lung carcinoma.